Sareh Seyedkazemi, PharmD

Disease Area Strategic Coordinator
Janssen Scientific Affairs, LLC
Titusville, NJ

Disclosure: Janssen: Employee, Shareholder

Presentation(s):

• 887 - High Rates of Virologic Suppression Achieved in HIV-1–Infected Adults Rapidly Starting Antiretroviral Therapy (ART) With the Single-Tablet Regimen (STR) of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) 800/150/200/10 mg Regardless of Baseline Disease Characteristics: Week 48 Subgroup Analyses From the Phase 3 DIAMOND Trial

  Thursday, October 3
  4:15 PM – 4:30 PM